Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2012

View Archived Issues

Rexahn Pharmaceuticals obtains clearance for first-in-human RX-3117 study

Tesetaxel is active in patients with gastroesophageal cancer

Therapeutic investigation of dacomitinib expands to gastric cancer

MLN-8237 investigated with cisplatin in gastrointestinal cancer models

Alantos identifies potent disease-modifying candidate osteoarthritis drug

BrainStorm reports initial safety and efficacy data on NurOwn stem cell product

Vivalis and Sanofi Pasteur extend collaboration

Noscira completes randomization in tideglusib study

New Japanese approval of controlled-release paroxetine product

Trimel Pharmaceuticals advances phase III CompleoTRT study

Novelos Therapeutics starts phase Ib trial of radiotherapeutic agent in advanced solid tumors

Bristol-Myers Squibb patents novel chemokine CCR1 receptor ligands

Novel chemokine CCR2 receptor antagonists disclosed by Janssen

Chilean team presents new biomarker of gastric cancer progression

New insulin-like growth factor 1 receptor antagonists designed in Japan

FOB Synthesis claims new antibacterial agents

New PET imaging agents synthesized by Bracco Imaging

Trimesta studied in new phase II trial for cognitive dysfunction in MS

FDA clears clinical testing of oral epidermal growth factor receptor mutant-selective inhibitor

Hybrigenics files clinical trial application for inecalcitol in CLL

New JTE-013 analogues prepared in Italy

Ferrer cleared to begin phase III trials of ozenoxacin cream

Cell Therapeutics anticipates CHMP's opinion on Pixuvri MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.